Catalyst
Key milestones include the completion of dosing phases and the reporting of pharmacokinetic and safety data.
Humanexa recommends Monitor.
Date
July 6, 2026
Phase
N/A
Status
watch
Signal score
6.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.